Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARIA MASCOLO

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1194793042
CMS profile
144821
Location
RINCON, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$2,377.15

148 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,265.45 146
Education $111.70 2

By paying entity

PY2019 · entire year · sorted by reported total

Page 3 of 3; records 101–148 of 148 matching records. This page contains 48 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARIA MASCOLO

NPI 1194793042 · CMS profile ID 144821

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

RINCON, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–148 of 148 matching records. This page contains 48 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1194793042?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARIA MASCOLO, NPI 1194793042, CMS profile ID 144821. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–148 of 148 matching records. This page contains 48 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1194793042?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). MARIA MASCOLO, NPI 1194793042, CMS profile ID 144821. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–148 of 148 matching records. This page contains 48 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1194793042?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
MARIA MASCOLO, NPI 1194793042, CMS profile ID 144821, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–148 of 148 matching records. This page contains 48 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1194793042?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

148 matching records · $2,377.15 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 148 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–148 of 148.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $17.4604/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685186321 CMS
GlaxoSmithKline, LLC. $16.4304/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670893599 CMS
GlaxoSmithKline, LLC. $18.3604/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671019085 CMS
Regeneron Healthcare Solutions, Inc. $25.5904/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673430069 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.1004/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700124023 CMS
Mylan Specialty L.P. $21.3704/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694778929 CMS
GlaxoSmithKline, LLC. $11.5904/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670924987 CMS
AstraZeneca Pharmaceuticals LP $11.7004/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685292881 CMS
GlaxoSmithKline, LLC. $0.5803/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671278131 CMS
United Therapeutics Corporation $18.9203/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703102659 CMS
Allergan Inc. $17.2703/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670777999 CMS
Electromed, Inc. $13.3603/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705230635 CMS
Mylan Specialty L.P. $21.2303/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694810849 CMS
Electromed, Inc. $15.8303/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705230623 CMS
GlaxoSmithKline, LLC. $10.5103/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670428797 CMS
Sunovion Pharmaceuticals Inc. $12.3203/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688157907 CMS
Sunovion Pharmaceuticals Inc. $12.2003/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688157909 CMS
Actelion Pharmaceuticals US, Inc. $16.4603/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659759756 CMS
Electromed, Inc. $18.9603/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705230619 CMS
GlaxoSmithKline, LLC. $14.3103/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671509711 CMS
JAZZ PHARMACEUTICALS INC. $16.1103/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684179427 CMS
AstraZeneca Pharmaceuticals LP $17.7302/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685441475 CMS
GlaxoSmithKline, LLC. $0.7802/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670968043 CMS
PFIZER INC. $16.8802/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671890583 CMS
Philips Electronics North America Corporation $16.7602/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684073391 CMS
GlaxoSmithKline, LLC. $15.0902/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670793795 CMS
Sunovion Pharmaceuticals Inc. $14.7302/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688157903 CMS
Sunovion Pharmaceuticals Inc. $14.5002/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688157905 CMS
GlaxoSmithKline, LLC. $10.1602/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671207805 CMS
Grifols USA, LLC $18.0902/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692580789 CMS
Electromed, Inc. $16.8202/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705230641 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $23.3402/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700124025 CMS
GENZYME CORPORATION $24.6002/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693910323 CMS
AstraZeneca Pharmaceuticals LP $18.8202/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685218933 CMS
Mylan Specialty L.P. $23.8802/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694774449 CMS
GlaxoSmithKline, LLC. $17.8201/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671478013 CMS
GlaxoSmithKline, LLC. $15.0001/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670612235 CMS
GlaxoSmithKline, LLC. $2.4801/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671450337 CMS
Philips Electronics North America Corporation $17.1001/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684073393 CMS
Allergan Inc. $11.2001/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670777995 CMS
GlaxoSmithKline, LLC. $12.4201/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671465937 CMS
AstraZeneca Pharmaceuticals LP $13.6201/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685646855 CMS
GENZYME CORPORATION $22.1401/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693990305 CMS
Genentech USA, Inc. $17.0801/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681218349 CMS
Sunovion Pharmaceuticals Inc. $16.8401/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688157901 CMS
AstraZeneca Pharmaceuticals LP $67.7101/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685961919 CMS
GlaxoSmithKline, LLC. $8.8101/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670872189 CMS
Grifols USA, LLC $15.9101/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692577847 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,377.15 148
PY2020 $1,667.65 103
PY2021 $9,623.59 154
PY2022 $29,031.77 213
PY2023 $102,979.29 247
PY2024 $91,107.70 242
PY2025 $121,256.44 286

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $548,658.98 193
PY2024 Principal investigator $425,763.90 200
PY2023 Principal investigator $423,172.54 115
PY2022 Principal investigator $529,728.15 160
PY2021 Principal investigator $156,482.61 68
PY2020 Principal investigator $76,981.93 17
PY2019 Principal investigator $146,625.80 23

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

193 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $1,339.39 12/19/2025 Non-covered Recipient Entity
CENTRICITY R RINCON PULMONOLOGY
AN INTERVENTIONAL PHASE 23 RANDOMIZED DOUBLEBLIND THIRD PARTYUNBLINDED PLACEBOCONTROLLED PARALLELGROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH MODERATETOSEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE COPD No dispute reported 06/30/2026 1228814885
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 12/04/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A PROSPECTIVE COHORT STUDY OF PATIENTS WITH REFRACTORY OR UNEXPLAINED No dispute reported 06/30/2026 1192133727
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.99 11/24/2025 Non-covered Recipient Entity
Centricity Research Rincon Pulmonology
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737941
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.71 11/24/2025 Non-covered Recipient Entity
Centricity Research Rincon Pulmonology
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737943
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3.84 11/24/2025 Non-covered Recipient Entity
Centricity Research Rincon Pulmonology
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737945
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $30.10 11/24/2025 Non-covered Recipient Entity
Centricity Research Rincon Pulmonology
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737947
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $93.50 11/24/2025 Non-covered Recipient Entity
Centricity Research Rincon Pulmonology
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737949
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.32 11/24/2025 Non-covered Recipient Entity
Centricity Research Rincon Pulmonology
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737951
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.65 11/24/2025 Non-covered Recipient Entity
Centricity Research Rincon Pulmonology
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737953
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.65 11/24/2025 Non-covered Recipient Entity
Centricity Research Rincon Pulmonology
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737955
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $33.00 11/24/2025 Non-covered Recipient Entity
Centricity Research Rincon Pulmonology
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737957
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2.88 11/24/2025 Non-covered Recipient Entity
Centricity Research Rincon Pulmonology
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737959
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6.41 11/24/2025 Non-covered Recipient Entity
Centricity Research Rincon Pulmonology
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737961
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $45.61 11/24/2025 Non-covered Recipient Entity
Centricity Research Rincon Pulmonology
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737963
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $30.10 11/24/2025 Non-covered Recipient Entity
Centricity Research Rincon Pulmonology
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737965
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $60.20 11/24/2025 Non-covered Recipient Entity
Centricity Research Rincon Pulmonology
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737967
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $44.00 11/24/2025 Non-covered Recipient Entity
Centricity Research Rincon Pulmonology
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233737969
Principal investigator 1 GlaxoSmithKline, LLC. $3,000.00 11/07/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A PROSPECTIVE COHORT STUDY OF PATIENTS WITH REFRACTORY OR UNEXPLAINED No dispute reported 06/30/2026 1192133733
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 11/07/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A PROSPECTIVE COHORT STUDY OF PATIENTS WITH REFRACTORY OR UNEXPLAINED No dispute reported 06/30/2026 1192133760
Principal investigator 1 GlaxoSmithKline, LLC. $8,000.00 11/07/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A PROSPECTIVE COHORT STUDY OF PATIENTS WITH REFRACTORY OR UNEXPLAINED No dispute reported 06/30/2026 1192133766
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,300.66 10/15/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738667
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,359.00 10/13/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738659
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $700.00 10/13/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738661
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $375.00 10/13/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738663
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,250.00 10/13/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738671
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $800.00 10/13/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738675
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,479.00 10/13/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738677
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,500.00 10/13/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738693
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $250.00 10/13/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738695
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $75.00 10/13/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738697
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $86.31 10/02/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738657
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,320.68 10/02/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738665
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $214.99 10/02/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738669
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $86.31 10/02/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738673
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,320.68 10/02/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738679
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,431.65 10/02/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738681
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,320.68 10/02/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738683
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $86.31 10/02/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738685
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $86.31 10/02/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738687
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,320.68 10/02/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738689
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,320.68 10/02/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738691
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,622.62 10/02/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738699
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $458.00 10/02/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738701
Principal investigator 1 Verona Pharma, Inc. $2,300.00 10/01/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891729
Principal investigator 1 Insmed, Inc. $48.00 09/30/2025 Non-covered Recipient Entity
IACT Health - Roswell - IACT - HyperCore - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189645862
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 08/27/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192130542
Principal investigator 1 Genentech, Inc. $925.00 08/20/2025 Non-covered Recipient Entity
INSTITUTE FOR THE ADVANCEMENT
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211616064
Principal investigator 1 Genentech, Inc. $3,493.00 08/20/2025 Non-covered Recipient Entity
INSTITUTE FOR THE ADVANCEMENT
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211616067
Principal investigator 1 Genentech, Inc. $800.00 08/20/2025 Non-covered Recipient Entity
INSTITUTE FOR THE ADVANCEMENT
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211616072
Principal investigator 1 Genentech, Inc. $750.00 08/20/2025 Non-covered Recipient Entity
INSTITUTE FOR THE ADVANCEMENT
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211616075
Principal investigator 1 AstraZeneca Pharmaceuticals LP $20,306.59 08/12/2025 Non-covered Recipient Entity
CR SERVICES ACQUSITION US, LLC
Randomized Double blind Placebo controlled Parallel Group Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD No dispute reported 06/30/2026 1185542816
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 08/06/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738651
Principal investigator 1 GlaxoSmithKline, LLC. $700.00 08/01/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192124382
Principal investigator 1 GlaxoSmithKline, LLC. $800.00 08/01/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192125579
Principal investigator 1 GlaxoSmithKline, LLC. $1,750.00 08/01/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192125586
Principal investigator 1 GlaxoSmithKline, LLC. $1,750.00 08/01/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192125598
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 08/01/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192125615
Principal investigator 1 GlaxoSmithKline, LLC. $5,500.00 08/01/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192130583
Principal investigator 1 GlaxoSmithKline, LLC. $700.00 07/30/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192130577
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 07/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184221166
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $41.85 07/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184221170
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18.90 07/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184221172
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 07/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184221174
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $518.23 07/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184221176
Principal investigator 1 Verona Pharma, Inc. $10,000.00 07/25/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891675
Principal investigator 1 Verona Pharma, Inc. $1,800.00 07/25/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891677
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $275.00 07/07/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738653
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $510.30 07/07/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738655
Principal investigator 1 SANOFI PASTEUR INC. $400.00 06/02/2025 Non-covered Recipient Entity
Cr Services Acquisition Us Llc
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. No dispute reported 06/30/2026 1226088308
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196929
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18.90 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196931
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $41.85 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196933
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196935
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.00 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196937
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18.90 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196939
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18.20 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196941
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18.20 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.50 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196945
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.50 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196947
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.00 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196949
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196951
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196953
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $41.85 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196955
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.50 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196957
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196959
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18.20 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196963
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196965
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.60 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196967
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196969
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196971
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196973
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.00 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196975
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196979
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196981
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196983
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18.90 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196985
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18.90 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196987
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196989
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196991
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.50 05/19/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184196993
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $90.00 05/09/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738637
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $208.24 05/09/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738639
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $900.00 05/09/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738641
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $89.05 05/09/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738643
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $100.01 05/09/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738645
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $117.82 05/09/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738647
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $246.60 05/09/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738649
Principal investigator 1 AstraZeneca Pharmaceuticals LP $17,410.24 05/02/2025 Non-covered Recipient Entity
CR SERVICES ACQUSITION US, LLC
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma No dispute reported 06/30/2026 1185542812
Principal investigator 1 GlaxoSmithKline, LLC. $25.00 04/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192125610
Principal investigator 1 GlaxoSmithKline, LLC. $93.84 04/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192130555
Principal investigator 1 GlaxoSmithKline, LLC. $193.20 04/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192130561
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $518.23 04/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190263
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $518.23 04/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190265
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $518.23 04/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190267
Principal investigator 1 GlaxoSmithKline, LLC. $193.20 04/09/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192124377
Principal investigator 1 GlaxoSmithKline, LLC. $3,845.37 04/09/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192125592
Principal investigator 1 GlaxoSmithKline, LLC. $93.84 04/09/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192130548
Principal investigator 1 GlaxoSmithKline, LLC. $25.00 04/09/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192133722
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,623.22 04/04/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 1185542814
Principal investigator 1 SANOFI PASTEUR INC. $400.00 03/13/2025 Non-covered Recipient Entity
Cr Services Acquisition Us Llc
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. No dispute reported 06/30/2026 1226088217
Principal investigator 1 Insmed, Inc. $48.00 02/21/2025 Non-covered Recipient Entity
IACT Health - Roswell - IACT - HyperCore - PPDS
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189645860
Principal investigator 1 SANOFI PASTEUR INC. $5,891.10 02/18/2025 Non-covered Recipient Entity
Cr Services Acquisition Us Llc
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. No dispute reported 06/30/2026 1226088261
Principal investigator 1 AstraZeneca Pharmaceuticals LP $41,578.21 02/12/2025 Non-covered Recipient Entity
CR SERVICES ACQUSITION US, LLC
A Randomised Placebo-Controlled Double-Blind Multi-Centre 4-week 3-way Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide Glycopyrronium and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared with BGF Delivered by MDI HFA in Participants with Chronic Obstructive Pulmonary Disease No dispute reported 06/30/2026 1185542810
Principal investigator 1 GlaxoSmithKline, LLC. $322.41 02/11/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192130535
Principal investigator 1 GlaxoSmithKline, LLC. $2,488.12 02/10/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192130569
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,003.04 02/05/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738537
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $89.05 02/05/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738541
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $275.00 02/05/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738543
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $90.00 02/05/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738555
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $90.00 02/05/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738557
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $625.00 02/05/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738567
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $200.00 02/05/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738575
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $100.01 02/05/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738577
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $117.82 02/05/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738583
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $180.00 02/05/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738585
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $180.00 02/05/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738589
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $25.00 02/05/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738593
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $246.60 02/05/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738595
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $208.24 02/05/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738603
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,075.00 02/05/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738609
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $561.70 02/05/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738615
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,397.60 02/05/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738617
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $134.26 02/05/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738629
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,950.00 02/05/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738633
Principal investigator 1 Eli Lilly and Company $751.70 01/31/2025 Non-covered Recipient Entity
COLUMBUS CLINICAL RESEARCH INC
A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) No dispute reported 06/30/2026 1187878799
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.41 01/31/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184151545
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.41 01/31/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184151547
Principal investigator 1 GlaxoSmithKline, LLC. $2,392.57 01/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192125572
Principal investigator 1 GlaxoSmithKline, LLC. $2,220.42 01/28/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192125605
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $117.82 01/22/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738539
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $270.00 01/22/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738549
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,003.04 01/22/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738561
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $134.26 01/22/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738569
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $100.01 01/22/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738573
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,397.60 01/22/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738581
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $246.60 01/22/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738591
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $53.43 01/22/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738599
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,100.00 01/22/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738601
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $89.05 01/22/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738605
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $208.24 01/22/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738611
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $561.70 01/22/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738623
Principal investigator 1 SANOFI PASTEUR INC. $113,011.30 01/22/2025 Non-covered Recipient Entity
Cr Services Acquisition Us Llc
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. No dispute reported 06/30/2026 1226088267
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,183.68 01/17/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738545
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,098.74 01/17/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738547
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10,210.61 01/17/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738551
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8,825.54 01/17/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738553
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,183.68 01/17/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738559
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8,825.54 01/17/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738563
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8,825.54 01/17/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738565
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,431.65 01/17/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738571
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10,210.61 01/17/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738579
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,183.68 01/17/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738587
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8,452.90 01/17/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738597
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,183.68 01/17/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738607
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,183.68 01/17/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738613
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,379.65 01/17/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738619
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8,452.90 01/17/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738621
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8,825.54 01/17/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738625
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $923.38 01/17/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738627
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,098.74 01/17/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738631
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $789.12 01/17/2025 Non-covered Recipient Entity
CR Services Acquisition US, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233738635
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 01/16/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184148013
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 01/16/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184148015
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 01/16/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184148017
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 01/16/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184148019
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 01/16/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184148021
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.00 01/16/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184148023
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18.90 01/16/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184148025
Principal investigator 1 Eli Lilly and Company $117,414.45 01/07/2025 Non-covered Recipient Entity
CR SERVICES ACQUISITION US LLC
A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) No dispute reported 06/30/2026 1187883798
Principal investigator 1 AstraZeneca Pharmaceuticals LP $16,469.00 01/03/2025 Non-covered Recipient Entity
CR SERVICES ACQUSITION US, LLC
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185542808